Data from Viral Kinetic Study Showed Rapid Reduction of HCV RNA with ALS-2200 (VX-135), Vertex's Ora
Data from Viral Kinetic Study Showed Rapid Reduction of HCV RNA with ALS-2200 (VX-135), Vertex's Oral Nucleotide Analogue in Development for the Treatment of Hepatitis C - 4.54 log 10 median reduction ...
Aim is to combine ALS-2200 and ALS-2158 with approved Incivek and investigational candidate VX-222. Vertex Pharmaceuticals is paying Alios BioPharma $60 million up front for worldwide rights to two of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback